0.77
-0.032(-4.02%)
Currency In USD
| Previous Close | 0.8 |
| Open | 0.78 |
| Day High | 0.79 |
| Day Low | 0.75 |
| 52-Week High | 2.35 |
| 52-Week Low | 0.36 |
| Volume | 6.51M |
| Average Volume | 4.81M |
| Market Cap | 127.38M |
| PE | -1.02 |
| EPS | -0.75 |
| Moving Average 50 Days | 1.48 |
| Moving Average 200 Days | 0.94 |
| Change | -0.03 |
If you invested $1000 in Tenaya Therapeutics, Inc. (TNYA) since IPO date, it would be worth $49.84 as of December 17, 2025 at a share price of $0.765. Whereas If you bought $1000 worth of Tenaya Therapeutics, Inc. (TNYA) shares 3 years ago, it would be worth $375 as of December 17, 2025 at a share price of $0.765.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
GlobeNewswire Inc.
Dec 11, 2025 9:01 PM GMT
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Si
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
GlobeNewswire Inc.
Dec 11, 2025 9:01 PM GMT
MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with SitesSOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
GlobeNewswire Inc.
Nov 08, 2025 4:25 PM GMT
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses Longer-term Follow Up of Cohort 1 Patients Showed Co